Comparative Pharmacology
Head-to-head clinical analysis: KANAMYCIN SULFATE versus NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANAMYCIN SULFATE versus NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN.
KANAMYCIN SULFATE vs NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing mRNA misreading.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a polypeptide antibiotic that disrupts bacterial cell membrane permeability by interacting with phospholipids. Gramicidin is a polypeptide antibiotic that increases cell membrane permeability by forming ion channels, leading to bacterial cell death.
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
Instill 2 drops (or appropriate amount) into affected eye(s) every 2-4 hours for 7-10 days. Frequency may be increased to every 1-2 hours in severe infections. Ophthalmic suspension, not for injection.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (CrCl <10 mL/min).
Neomycin: 2-3 hours (normal renal function); polymyxin B: 6-8 hours; gramicidin: ~10 hours (estimated from topical absorption). Prolonged in renal impairment, especially for polymyxin B.
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Renal: ~95% for neomycin (unchanged), minimal for polymyxin B (1-10% unchanged) and gramicidin (<1%). Fecal: 50-60% for polymyxin B (biliary), ~1% for neomycin.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic